Reply to: Comments on “The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients”
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34431 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Arndt Borkhardt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Neoplasms. Die Arbeit nennt 3 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
- German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Düsseldorf, Germany.
ORCID-Profile: Rabea Wagener
Zitieren
APA
Borkhardt, A., Wagener, R., & Brozou, T. (2023). Reply to: Comments on “The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients”. International Journal of Cancer. https://doi.org/10.1002/ijc.34431
Vancouver
Borkhardt A, Wagener R, Brozou T. Reply to: Comments on “The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients”. International Journal of Cancer. 2023. doi:10.1002/ijc.34431
BibTeX
@article{Borkhardt2023,
author = {Borkhardt, Arndt and Wagener, Rabea and Brozou, Triantafyllia},
title = {Reply to: Comments on “The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients”},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34431}
}
EUVIMED